These include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Those with pre-existing GI conditions, including gastroparesis, inflammatory bowel disease, or chronic pancreatitis, should avoid retatrutide entirely
GLP1 medications are peptidebased therapies, and they are in a different category than most wellnessmarket peptide stacks. Within NOVA Slim, we may discuss supportive peptidebased or nutrientbased options when they are clinically appropriate and when they make the program easier to follow, for example, support around recovery, sleep, training tolerance, or adherence during appetite change
For best results, use daily for 90 days
Zone 2: Mid-cheek and zygomatic Mid-cheek volume loss is the single most common complaint in GLP-1 patients